

STANDARD OPERATING PROCEDURE	Document Number: BIO-OPR-006	Version Number 2.0	Signature
Policies and Procedures for Financial Conflict of Interest	Effective Date: 07/01/2023	Page: 1 of 4	

1.0 General Police

Objective research is of paramount importance to Bioptics Technology LLC (BOT) and our subgrantees and defined vendors herein, to ensure public trust and meet scientific, program and ethical goals of our National Institutes Health (NIH) grant efforts. To address the increasing complexities related to financial interests held by biomedical and behavioral researchers, the Public Health Service (PHS) and the Office of the Secretary department of Health and Human Services (HHS) has published 42 CFR Part 50. BOT has addressed the requirements (including those of sub-level vendors) but will continue to update this policy as needed.

Effective June 13, 2023, BOT requires that each investigator, subrecipient, subgrantee and collaborator affiliate BOT, by NIH or any other applicable grant or contract, be in compliance with 42 CFR Part 50, Subpart F for PHS grants and cooperative agreements (and 45 CFR Part 94 for contracts). This legislation spells out NIH's commitment to preserving the public's trust that the research supported by them is conducted without bias and with the highest scientific and ethical standards.

The following are key term definitions of BOT policy guidance for principal or program investigators, subrecipients, subgrantees and collaborators affiliated with BOT.

2.0 Definitions and Procedures

2.1 Investigator

Any individual who is independently responsible for the design, conduct, or reporting of research at BOT, which includes, but may not be limited to principal investigators, co-investigators and key personnel.

2.2 Training Requirement

Investigators and all defined sub-level vendors are required to complete training related to Financial Conflict of Interest (FCOI). If any conflicts of interest are found or known, they must be disclosed. Information and other resources developed by NIH will be updated as appropriate and can be accessed through the NIH Web site. (https://grants.nih.gov/grants/policy/nihgps/HTML5/section_4/4.1.10_financial_conflict_of_interest.htm).

Bioptics Technology

STANDARD OPERATING PROCEDURE	Document Number: BIO-OPR-006	Version Number 2.0	Signature
Policies and Procedures for Financial Conflict of Interest	Effective Date: 07/01/2023	Page: 2 of 4	

3.0 Significant Financial Interest (SFI)

A financial interest consisting of one or more of the following interests of the Investigator (and those of the Investigator's spouse and dependent children) that reasonable appears to be related to the Investigator's institutional responsibilities:

With regard to any non-publicly traded entity, a significant financial interest exists if the value of any remunerations from the entity in the twelve months preceding the disclosure, when aggregated, exceeds \$5,000, or when the Investigator (or the Investigator's spouse or dependent children) holds any equity interests (e.g. stock, stock options, or other ownership interest) or Intellectual property rights and interests (e.g. patents, copyrights), upon receipt of income related to such rights and interests.

Investigators also must disclose the occurrence of any reimbursed or sponsored travel (i.e., that which is paid on behalf of the Investigator and not reimbursed to the Investigator so that the exact monetary value may not be readily available) related to their institutional responsibilities; provided, however, that this disclosure requirement does not apply to travel that is reimbursed or sponsored by a federal, state or local government agency, an institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, medical center, or research institute that is affiliated with an Institution of higher education. The Institution's FCOI policy will specify the details of this disclosure, which will include, at a minimum, the purpose of the trip, the identity of the sponsor/organizer, the destination, and the duration. In accordance with the Institution's FCOI policy, the institutional official(s) will determine if further information is needed, including a determination or disclosure of monetary value, in order to determine whether the travel constitutes a FCOI with the PHS-funded research.

The term significant financial interest does not include the following types of financial interests: salaries, royalties or other remuneration paid by the institution to the Investigator if the Investigator is currently employed or otherwise appointed by the Institution, including intellectual property rights assigned to the Institution and agreements to share in royalties related to such rights; any ownership interest in the Institution held by the investigator, if the Institution is a commercial or for profit organization; income from investment vehicles, such as mutual funds and retirements accounts, as long as the Investigator does not directly, control the investment decisions made in these vehicles; income from seminars, lectures or teaching engagements sponsored by a federal, state or local government agency an Institution of higher

Bioptics Technology

STANDARD OPERATING PROCEDURE	Document Number: BIO-OPR-006	Version Number 2.0	Signature
Policies and Procedures for Financial Conflict of Interest	Effective Date: 07/01/2023	Page: 3 of 4	

education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, research institute that is affiliated with an Institution of higher education; or income from service on advisory committees or review panels for a federal, state or local government agency an Institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education.

4.0 Financial Conflict of Interest (FCOI)

A Financial conflict of interest exists when BOT reasonably determines that a Significant Financial Interest (defined above) could directly and significantly affect the design, conduct or reporting of NIH-funded research.

5.0 Management of a FCOI

Means taking action to address a FCOI, which can include reducing or eliminating the FCOI, to ensure, to the extent possible, that the design, conduct, and reporting of research will be free from bias

6.0 Disclosures/Reporting Process

BOT designated official(s) will review all "disclosure" and evaluate whether they contain any FCOI. If no FCOI is found the disclosures will be filed in the SFI folder. If a FCOI is identified it will be put on the FCOI report through the eRA Commons FCOI module prior to expending any funds. If any interests are identified as conflict of interest subsequent to the initial report they must be reported to BOT within 30 days. BOT will then report it to the PHS awarding component that has issued the award within 60 days.

Each Investigator must submit an updated disclosure of an SFI not less than annually. If a PHS-funded project is conducted by an investigator with a conflict that was not disclosed or managed, BOT is required to disclose the conflict in each public presentation related to the results of the research.

7.0 Records Management

The records of all financial disclosures and all actions taken by BOT will be maintained for at least three years from the date of submission of the final expenditures report.

Bioptics Technology

STANDARD OPERATING PROCEDURE	Document Number: BIO-OPR-006	Version Number 2.0	Signature
Policies and Procedures for Financial Conflict of Interest	Effective Date: 07/01/2023	Page: 4 of 4	

8.0 Compliance for Non-Performance

If an Investigator fails to comply with FCOI policy, within 120 days shall complete a retrospective review of the Investigator's activities to determine bias. If a bias is found, BOT shall submit a mitigation report to the NIH, in accordance with 42 CFR 50.605(b)(3), that shall address the impact of bias on the research project and the actions it has taken to mitigate the bias. BOT will work with the Investigator to set up an FCOI management plan to mitigate the situation. Companywide, BOT is required to mandate the Investigator disclose the FCOI in each public presentation research results if it was not reported up front. In extreme cases of bias, the Investigator may lose the right to work on the project or receive any future NIH funding.

9.0 Revision History

Version Number	Section Number	Description of Document Revision and Reason
1.0	All	Creation of procedure
2.0	All	Company logo changed